Navigation Links
Almac's Clinical Technologies Business Unit Again Receives 'Best Places to Work in PA 2010' Award
Date:11/10/2010

one of the Best Places to Work in PA for 2010. The awards program, created in 2000, is one of the first statewide programs of its kind in the country. The program is a public/private partnership between the Team Pennsylvania Foundation, the Pennsylvania Department of Community and Economic Development, and the Central Penn Business Journal.

This survey and awards program was designed to identify, recognize, and honor the best places to be employed in Pennsylvania, benefiting the state's economy, its workforce, and businesses.

Companies from across the state entered the two-part process to determine the 100 Best Places to Work in PA. The first part of this process was evaluating each nominated company's workplace policies, practices, philosophies, systems, and demographics. The second part consisted of an employee survey to measure the employee experience. The combined scores determined the top companies and the final ranking. Best Companies Group managed the overall registration and survey process.

Jim Murphy, President of Almac's Clinical Technologies' business unit, comments on receiving the award: "Almac is honored to receive the Best Places to Work in PA Award for the second year in a row. Almac's core values are Quality, Service, Innovation, and People. Among these values, 'people' is the most critical because Almac's employees are the key to our ability to fulfill the other three core values. In recognition of this fact, Almac invests heavily in employment development and fosters a culture that creates a positive, collaborative, and productive working environment."

Almac's Clinical Technologies unit will be recognized at the Best Places to Work in PA evening awards ceremony on Tuesday, November 30, 2010, at the Lancaster County Convention Center in Lancaster, PA. Rankings will be revealed at the ceremony.

W: http://www.almacgroup.com


'/>"/>
SOURCE Almac Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
3. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
4. Association of Clinical Research Organizations (ACRO) Welcomes Clinilabs and RPS as New Members
5. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
6. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
7. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
8. /R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/
9. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
10. Ondine Announces Presentation of Positive Clinical Trial Results at the American Academy of Periodontologys 94th Annual Meeting
11. ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... MA (PRWEB) November 21, 2014 ... key investors will gather on December 3rd at ... Biotech Conferences series. GeneticRx will take place at ... Medical School and will discuss the present and ... therapy, exon skipping, and gene editing—as well as ...
(Date:11/22/2014)... November 21, 2014 RURO, Inc., ... provider, has released Limfinity® version 5.1.4. , RURO’s ... of Limfinity® than ever in RURO’s 8 year ... minority framework enhancement. Limfinity® version 5.1.4 is the ... and beyond bug fixes! , Limfinity® 5.1.4 release ...
(Date:11/22/2014)... 2014 The “Chiral Chromatography Columns ... Material (Metal, Glass, Plastic), by Application [GC, LC ... Forecast to 2018” analyses and studies the major ... America, Europe, Asia, and Rest of the World. ... figures spread through 135 pages and in-depth TOC ...
(Date:11/22/2014)... 2014  The element of surprise has been a ... strike without warning. Until now, epidemiologists had nothing to ... outbreak, resulting in suboptimal responses to both the H1N1 ... Photo - http://photos.prnewswire.com/prnh/20141121/160242 ... because virus gene structural changes have been found that ...
Breaking Biology Technology:Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2RURO Announces Limfinity® version 5.1.4 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5Viruses' Advantage of Surprise is Lost 2
... , SAN DIEGO, Calif., July ... and its subsidiary Tissue Repair Company (TRC) today provided an ... study and announced plans to provide detailed safety and efficacy ... September. The MATRIX trial, a prospective, randomized, double-blind, placebo-controlled ...
... , , SUNRISE, Fla., July ... to delivering intelligent devices and biologics that help monitor, diagnose and ... FDA cleared a phase I clinical trial for MyoCell SDF-1 (Stromal ... REGEN trial will enroll 15 patients in a multicenter, randomized, dose ...
... , , CINCINNATI, July 27 ... full-service clinical research organization, today appointed Stephen Cutler, PhD, as ... (COO) effective immediately. Dr. Cutler brings to Kendle more than ... the CRO and biopharmaceutical industries to position the Company for ...
Cached Biology Technology:Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications 2Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications 3Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications 4Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications 5United States FDA Clears the REGEN Trial to Test Bioheart's Combination Gene and Stem Cell Therapy in Heart Failure Patients 2United States FDA Clears the REGEN Trial to Test Bioheart's Combination Gene and Stem Cell Therapy in Heart Failure Patients 3United States FDA Clears the REGEN Trial to Test Bioheart's Combination Gene and Stem Cell Therapy in Heart Failure Patients 4Kendle Appoints Stephen Cutler, PhD Senior Vice President and Chief Operating Officer 2Kendle Appoints Stephen Cutler, PhD Senior Vice President and Chief Operating Officer 3
(Date:11/4/2014)... School of Medicine announced today that it is ... by the Bill & Melinda Gates Foundation. ... and Reproductive Sciences; and Vice Chair of Research ... Medicine will pursue an innovative global health and ... Assess Fetal Neurodevelopment.", Grand Challenges Explorations (GCE) funds ...
(Date:11/4/2014)... of Madagascar,s 101 species of lemurs are threatened with ... rainforests they call home. A new study by Rice ... on rainforest tree populations, which raises concerns about the ... rich biodiversity. , A large proportion of trees in ... in turn disperse the seeds of their fruit trees ...
(Date:11/3/2014)... , Nov. 3, 2014  NeuroSigma ® ... -based life sciences company focused on commercialization of ... for the treatment of neurological and neuropsychiatric ... Industrial Property has issued a Notice of Allowance ... application is co-owned by NeuroSigma and the Regents ...
Breaking Biology News(10 mins):Temple University School of Medicine receives Grand Challenges Explorations grant 2Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... in a virtual reality forest, will anyone hear an environmental message? ... cut down the make-believe redwood. New findings from Stanford researchers ... and told to saw through a towering sequoia until it crashed ... world than people who only imagined what it,s like to cut ...
... ST. LOUIS Saint Louis University researchers have identified ... fluid from tissues to lymphatic vessels. It may be possible ... organ to another organ and improve the effectiveness of vaccines. ... consisting of vessels in the body. It defends the body ...
... research by scientists at The Scripps Research Institute and collaborating ... that may provide a target for obesity and diabetes drugs. ... Cell Metabolism , the scientists describe a protein called ... signals that stimulate fat cell formation and turn off those ...
Cached Biology News:Stanford's virtual reality lab focuses on conservation 2Stanford's virtual reality lab focuses on conservation 3Outsmarting cancer cells: SLU scientists learn how they spread 2Scripps Research scientists find 'dual switch' regulates fat formation 2Scripps Research scientists find 'dual switch' regulates fat formation 3